# Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World

> **NCT05381753** · — · COMPLETED · sponsor: **CStone Pharmaceuticals** · enrollment: 61 (actual)

## Conditions studied

- Gastrointestinal Stromal Tumors

## Interventions

- **DRUG:** Avapritinib
- **DRUG:** Tyrosine kinase inhibitors other than avapritinib ( imatinib, sunitinib, et al )

## Key facts

- **NCT ID:** NCT05381753
- **Lead sponsor:** CStone Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-29
- **Primary completion:** 2024-09-30
- **Final completion:** 2024-09-30
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2026-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05381753

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05381753, "Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05381753. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*